SCHEMBL3950849

SCHEMBL3950849

Fc1ccc2nc(Cl)oc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 1/20 0.43
GABRP O00591 4/20 0.42
GABRD O14764 4/20 0.42
GABRA1 P14867 4/20 0.42
GABRB1 P18505 4/20 0.42
GABRG2 P18507 4/20 0.42
GABRB3 P28472 4/20 0.42
GABRA5 P31644 4/20 0.42
GABRA3 P34903 4/20 0.42
GABRA2 P47869 4/20 0.42
GABRB2 P47870 4/20 0.42
GABRA4 P48169 4/20 0.42
GABRE P78334 4/20 0.42
GABRA6 Q16445 4/20 0.42
GABRG1 Q8N1C3 4/20 0.42
GABRG3 Q99928 4/20 0.42
GABRQ Q9UN88 4/20 0.42
PSMB8 P28062 1/20 0.40
PSMB5 P28074 1/20 0.40
DAGLA Q9Y4D2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3095143 0.84 MPO (0.45) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL895172 0.79 PIK3CG (0.66) PIK3CGPSMB8PSMB5KDM4ES1PR3
SCHEMBL2490866 0.76 SMN1; SMN2 (0.49) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2541637 0.76 KDM4E (0.59) PIK3CGGABRPGABRDGABRA1GABRB1
SCHEMBL9898426 0.76 PIK3CG (0.61) PIK3CGGABRPGABRDGABRA1GABRB1
SCHEMBL11170826 0.76 PIK3CG (0.43) PIK3CGPSMB8PSMB5KDM4EKMT2A
SCHEMBL5542616 0.76 GABRP (0.42) PIK3CGGABRPGABRDGABRA1GABRB1
SCHEMBL2550867 0.76 ESR1 (0.58) PIK3CGKDM4EMAPT
SCHEMBL20552113 0.76 PIK3CG (0.43) PIK3CGPSMB8PSMB5DAGLAKDM4E
SCHEMBL15157800 0.76 NPC1 (0.58) PIK3CGPSMB8PSMB5KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0572893-A1 Fluor-benzoxazolyloxyacetamides BAYER AG (DE) 1993-12-08 EP claimed
US-12606551-B2 Salt of tetrahydroisoquinoline derivative, preparation method therefor, and medical use thereof ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2026-04-21 US disclosed
CN-117120423-B Indolylamine 2, 3-dioxygenase inhibitors, methods of preparing the same, and pharmaceutical compositions containing the same 柳韩洋行 2026-02-27 CN disclosed
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-05-13 US disclosed
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-04-08 US disclosed
CN-113880825-B Tetrahydroisoquinoline derivative salt, preparation method and medical application thereof 浙江海正药业股份有限公司 2025-03-14 CN disclosed
CN-119059967-A Diaryl amine compound with affinity with Tau protein, and preparation method and application thereof 北京师范大学 2024-12-03 CN disclosed
US-20240360155-A1 Benzodiazepine Derivatives as RSV Inhibitors ENANTA PHARM INC (US) 2024-10-31 US disclosed
US-20240174636-A1 NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2024-05-30 US disclosed
WO-2024084447-A2 AZETIDINYL BENZOXAZOLE COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS DONG-A ST CO., LTD. (KR) 2024-04-25 WO disclosed
US-7307095-B2 Osteoporosis; antiarthritic agents; antidiabetic agents; antiinflammatory agents; Alzheimer's disease; shock; central nervous stsrem disorders; anticancer agents; multiple sclerosis, (S)-2-(Benzooxazol-2-ylamino)-3-cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-propionamide IRM LLC (BM) 2007-12-11 US disclosed
US-20070123523-A1 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2007-05-31 US disclosed
US-7173051-B2 Inhibitors of cathepsin S IRM, LLC (BM) 2007-02-06 US disclosed
US-20050049244-A1 Inhibitors of cathepsin S IRM LLC (BM) 2005-03-03 US disclosed
WO-2004112709-A2 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2004-12-29 WO disclosed
EP-0883611-B1 AZOLYL PIPERAZINYL PHENYL OXAZOLIDINONE ANTIMICROBIALS UPJOHN CO (US) 2002-07-31 EP disclosed
EP-0883611-A1 AZOLYL PIPERAZINYL PHENYL OXAZOLIDINONE ANTIMICROBIALS PHARMACIA & UPJOHN COMPANY (US) 1998-12-16 EP disclosed
US-5736545-A ADMINISTERING TO TREAT BACTERIAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 1998-04-07 US disclosed
WO-1997030981-A1 AZOLYL PIPERAZINYL PHENYL OXAZOLIDINONE ANTIMICROBIALS PHARMACIA & UPJOHN COMPANY (US) 1997-08-28 WO disclosed
EP-0572893-A1 Fluor-benzoxazolyloxyacetamides BAYER AG (DE) 1993-12-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174636-A1 NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME IDO1, IDO2, INMT PIK3CG 2990/4885GABRP 3708/4885GABRD 3965/4885
US-20240360155-A1 Benzodiazepine Derivatives as RSV Inhibitors GABRA5, GABRA1, GABBR2 PIK3CG 2957/4885GABRP 11/4885GABRD 44/4885
US-20050049244-A1 Inhibitors of cathepsin S CTSS, CTSB, CTSZ PIK3CG 2676/4885GABRP 2825/4885GABRD 4652/4885
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 PIK3CG 2957/4885GABRP 11/4885GABRD 44/4885
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ACE, ACE2, SPCS3 PIK3CG 1395/4885GABRP 1313/4885GABRD 3961/4885
US-20070123523-A1 INHIBITORS OF CATHEPSIN S CTSS, CTSB, CTSZ PIK3CG 2676/4885GABRP 2825/4885GABRD 4652/4885
US-12606551-B2 Salt of tetrahydroisoquinoline derivative, preparation method therefor, and medical use thereof SLC5A2, SLC5A1, SLC5A11 PIK3CG 738/4885GABRP 1030/4885GABRD 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.